Physician profile
Vincent E Schaller
NPI 1730180696
$5,979.86
in general payments reported to CMS, 2019-2025
20 companies · $695 in 2025
The $695 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $487 · 2021: $570 · 2022: $1,070 · 2023: $1,428 · 2024: $971 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,670.21 | 2019-2025 | Ajovy, Austedo Xr |
| Abbvie INC. | $1,409.40 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $684.84 | 2023-2025 | |
| Lundbeck LLC | $573.55 | 2020-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $347.18 | 2022 | |
| Lilly USA, LLC | $317.34 | 2019-2025 | Emgality |
| Impel Pharmaceuticals INC. | $177.67 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $152.79 | 2021 | |
| Amgen INC. | $150.78 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $142.69 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $72.09 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $58.52 | 2019 | |
| Impel Pharmaceuticals LLC | $56.18 | 2024-2025 | Trudhesa |
| Axsome Therapeutics, INC. | $40.31 | 2025 | Symbravo |
| Allergan, INC. | $29.83 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $26.71 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.61 | 2023 | Nuedexta |
| Avanir Pharmaceuticals, INC. | $19.22 | 2022 | |
| Ani Pharmaceuticals, INC. | $17.52 | 2025 | Purified Cortrophin Gel |
| Brainscope Company, INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Schaller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.